Marketresearchnews

Tuesday, 8 June 2021

CPAP Devices Market 2020 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2027

Continuous positive airway pressure (CPAP) devices are used in the treatment of choice for obstructive sleep apnea syndrome. CPAP works by blowing air into the nose and throat. The blow causes a positive pressure to hold the upper airway open during sleep and thus helps in the treatment of snoring. This device typically used when the patient has a breathing problem. Additionally, it increases the air pressure in the throat to avoid airway from collapsing when breathing. It can be used every night at home while sleeping. The global CPAP market is majorly driven by increasing number of patients with sleep apnea, obesity, and other respiratory diseases. According to the World Health Organization (WHO), in 2016, more than 1.9 billion adults, above 18 years were overweight. Out of these over 650 million were obese. The report also suggests that over 340 million children and adolescents aged 5-19 were overweight or obese in 2016. Thus, rising number of patient with obesity generating the exponential demand for CPAP devices market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/939

According to the WHO, in 2016, around 39% of 41 million children under the age of 5 were overweight or obese. Advances in technology such as improved mask design, oral appliances, use of oxygen devices, rising healthcare expenditure, and increasing demand for the devices have fuelled the market growth. However, CPAP is not always effective since some patients find it uncomfortable and sometimes it shows adverse effects. The high cost of the devices and their adverse effect may slow the market growth.

Global continuous positive airway pressure (CPAP) devices market is expected to grow at a CAGR of 7.1% during the forecast period 2017-2027.

Segmentations

Global continuous positive airway pressure (CPAP) devices market is segmented on the basis of product type, features, automation, and end user

On the basis of the product type, it is segmented into CPAP motors, CPAP hoses, CPAP mask, and others.

On the basis of the features, it is segmented into the humidifier, portability, heated tubing, and others.

On the basis of the automation, it is segmented into manual and automatic.

On the basis of the end user, it is segmented into hospitals, private clinics, home care, and others.

Regional Analysis

The Americas hold the largest share of the global market owing to increasing incidence of obesity, unhealthy diet, and physical inactivity. According to the updated report by the Centers for Disease Control and Prevention (CDC) in 2017, a total number of adults diagnosed with chronic bronchitis in the past year was 9.3 million. The report further adds that around 3.8% of the total adult population in the U.S. diagnosed with chronic bronchitis, in 2016. Presence of well-developed technology, high health care spending, increased R&D activities, and the concentration of major companies have fuelled the growth of the market in this region.

Europe holds the second position followed by the Asia Pacific in the global CPAP devices market owing to the rising patient population diagnosed with respiratory diseases. Furthermore, the government support for research & development and availability of funds for research are likely to fuel the CPAP devices market growth over the forecast period.

Asia Pacific is the fastest growing CPAP devices market owing to unhealthy diet and associated lifestyle changes. Moreover, the increased presence of rapidly developing healthcare technology, high healthcare expenditure, R&D activities, and the concentration of major companies are fuelling the growth of the market in this region. Increasing demand for new treatment methods in countries like India and South Korea is likely to emerge as the fastest growing market across the globe.

On the other hand, the Middle East and Africa account for the lowest share of the global market owing to lack of technical knowledge and poor medical facilities.

Key Players

Some of key the players in the market are Medtronic (U.S.), Koninklijke Philips N.V. (the Netherlands), 3B Medical, Inc. (U.S.), Armstrong Medical Inc. (U.S.), ResMed (U.S.), Smiths Medical (U.S.), Apex Medical Corp. (Taiwan), Fisher & Phillips LLP (U.S.), Cardinal Health (U.S.) Beijing Dehaier Medical Technology Co., Ltd. (China), DeVilbiss Healthcare LLC (US), and Invacare Corporation (US).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/continuous-positive-airway-pressure-devices-market-939

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Needle-Free Diabetes Care Market Size, Share, Demand, Financial Overview, Key Developments, Swot Analysis and Forecast to 2027

Diabetes is a group of metabolic disorders, which is caused by insulin deficiency. Needle-free is a modern technique for administration of the medication to the patient. According to the International Diabetes Federation, about 420 million adult population was suffering from diabetes in 2016, which is increasing at the rate of 8.4% per year and is expected to reach 625 million by 2040. Increasing diabetic population is the major driving factor for the growth of the market. Moreover, increasing obese population, increasing healthcare expenditure, and strong encouragement from the government have also contributed to the growth of the market. According to research, smoking increases the possibility of diabetes; more than 60% of the global population smokes, this has increased the risk of diabetes and contributed to the growth of the market. On the other hand, factors such as, lack of awareness among people and higher cost are hampering the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/912

Global needle-free diabetic care market is expected to grow at a CAGR of 7.5% during the forecast period 2017-2023.

Segmentation

The global needle-free diabetic testing market is segmented on the basis of devices types into treatment devices and diagnostic devices. Treatment devices are further segmented: insulin jet injector, insulin pen, insulin inhaler, and insulin patch & pump. Diagnostic devices are also further segmented into continuous glucose monitoring and instant glucose monitoring. On the basis of treatment, the market is segmented into oral insulin, inhaled insulin, insulin patch, and others. On the basis of applications, the market is segmented into insulin delivery and others. On the basis of end users, the market is segmented into diagnostic centers, hospitals & clinics and other.

Regional Analysis

America dominates the global needle-free diabetes care market owing to large diabetic population. Apart from this, increasing number of obese people, changing lifestyle and increasing healthcare expenditure have boosted the growth of the market in America. Europe accounts for the second largest market, which is followed by Asia Pacific. Asia Pacific is the fastest growing region in the global market due to the presence of large diabetic population.

Key Players for Global Needle-free Diabetes Care Market

Antares Pharma, Inc. (US), Bioject Medical Technologies Inc. (US), Endo International plc (US), European Pharma Group (Netherland), PharmaJet (US), Medical International Technology, Inc. (US), Valeritas, Inc. (US), PenJet Corporation (US), INJEX Pharma AG (Germany), National Medical Products Inc. (US), Crossject SA (France), Zogenix, Inc. (US), 3M Company (US).

Intended Audience

Diabetic Needle Manufacturers
Medical Research Laboratories
Academic Medical Institutes and Universities
Independent Research Laboratories
Contract Research Organizations

The report for global needle-free diabetes care market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/needle-free-diabetes-care-market-912

Gene Therapy Market 2020 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2027

According to MRFR analysis, the global gene therapy market size is expected to register a CAGR of 40.7% during the forecast period of 2019 to 2025 and was valued at USD 524 million in 2018.

Gene therapy is a technique in which a piece of DNA is incorporated into the cell via a vector. The key players are investing in the manufacturing of cell and gene therapy treatments due to its target specificity. The gene therapy is mainly of two types, somatic gene therapy, and germline gene therapy, depending on the type of cells its targets.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8399

The growth of the global gene therapy market is attributed to various factors such as robust product pipeline, increasing investment by key players, and high prevalence of target diseases and demand for innovative medication. However, the high cost of product development and stringent regulatory policies are expected to curb the growth of the global gene therapy market. The global gene therapy market is currently dominated by several market players. The key players are involved in product launches and strategic collaborations to strengthen their market positions.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the increasing prevalence of gene therapy and rising per capita healthcare expenditure. The gene therapy market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European gene therapy market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The gene therapy market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing number of patients and raising awareness about the treatment methods, the market in Asia-Pacific is expected to be the fastest-growing. The gene therapy market in the Middle East & Africa has been divided into the Middle East and Africa.

Segmentation

The global gene therapy market has been segmented based on product, indication, and end user.

The market, based on product, has been divided into kymriah, luxturna, yescarta, zolgensma, strimvelis, zynteglo, imlygic, and others.

The global gene therapy market has on the basis of indication is segmented, into oncology, genetic diseases/ disorders, and others. The oncology segment is expected to hold the largest market share and to be the fastest-growing segment due to high prevalence of cancer and robust pipeline for cancer gene therapy.

The end-user segments of the market are hospitals & clinics, specialty treatment centers, and others. The hospitals & clinics segment is expected to hold the largest market share due to increasing number of hospitals. Also, hospitals are generally the first treatment choice for diseases.

Key Players

Some of the key players in the global gene therapy market are Amgen, Inc. (US), Novartis AG (Switzerland), Spark Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), uniQure N.V. (Netherlands), Orchard Therapeutics plc (UK), Celgene Corporation (US), Bristol-Myers Squibb Company (US), Thermo Fisher Scientific Inc. (US), CEVEC (Germany), and Lonza (Switzerland).

G-Protein Coupled Receptors Market Is Seeing Explosive Growth by Future Industry Winners: Forecast, 2020-2027

According to MRFR analysis, the global G protein coupled receptors market is expected to register a CAGR of 7.1% during the forecast period of 2019 to 2025 and was valued at USD 3,100 million in 2018.

GPCRs are the largest and the most diverse group of membrane receptors in eukaryotes. They are also called transmembrane domain receptors, 7TM receptors, serpentine receptor, and G protein-linked receptors. They detect molecules outside the cell and activate internal signal transduction pathways.

The growth of global G protein coupled receptors market is driven by various factors such as growing use of G protein combined receptors in medicating disclosure and advancement forms, increasing the number of drugs under clinical and preclinical studies that target these receptors. However, the high cost involved in the maintenance of GPCR cell lines is expected to curb the growth of the global G protein coupled receptor market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8356

Several market players currently dominate the global G protein coupled receptors market. The key players are involved in product launches and strategic collaborations to strengthen their market positions.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the presence of a large number of approved drugs that target G-protein coupled receptors. The G protein coupled receptors market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European G protein coupled receptors market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The G protein coupled receptors market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The rising number of approved drugs that target GPCRs has boosted the growth of the G protein coupled receptors market, the market in Asia-Pacific is expected to be the fastest-growing. The G protein coupled receptor market in the Middle East & Africa has been divided into the Middle East and Africa.

Segmentation

The global G protein coupled receptors market has been segmented based on the product, assay type, and application.

The market, based on product, has been divided into cell lines, detection kits, cell culture reagents, ligands, and others. The detection kits segment is likely to be the fastest during the review period as they are ready to use kits that includes all cells and reagents to perform functional GPCRs assay in live cells thus driving the growth of the global G protein coupled receptor market.

The global G protein coupled receptor market has been bifurcated, on the basis of assay type, into functional calcium assays, cAMP functional assays, cGMP assays, GTP gamma S binding assays, ß-Arrestin Functional Assays, internalization assays, and others. Calcium functional assays are the fastest segment as it has numerous advantages such as user configurability, ease in the estimation of calcium flux thus driving the growth of this segment in the GPCR market.

The global G protein coupled receptors market has been segmented, based on application into the cardiovascular system, oncology, immunology, respiratory system, central nervous system, and others. The cardiovascular system is the largest segment as angiotensin II, and β-adrenergic receptors provide therapy for a wide range of cardiovascular disease such as heart failure. Approximately 17.9 million people die each year from cardiovascular disease thus rising the growth of G protein coupled receptor market.

Key Players

Some of the key players in the global G protein coupled receptor market are Thermo Fisher Scientific, Inc., Cisbio, Promega Corporation, Abcam PLC, PerkinElmer Inc., Merck Group, HD Biosciences Co., Ltd, QIAGEN, Enzo Life Sciences, and Inc.BD.

Liver Cirrhosis Treatment Market – Qualitative Insights by 2027

Market Highlights

According to MRFR analysis, the global liver cirrhosis treatment market size is expected to register a CAGR of ~5.2% during the forecast period of 2019 to 2025 and was valued at USD 956.89 million in 2018.

Liver cirrhosis is basically the late-stage scarring of the liver caused due to various types of liver diseases and disorders such as alcoholism and hepatitis, among others. No symptoms are observed until the liver is extensively damaged. Complications of liver cirrhosis include portal hypertension, leg & abdomen swelling, splenomegaly, bleeding, infections, malnutrition, hepatic encephalopathy, jaundice, bone diseases, risk of liver cancer, and multi-organ failure.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8367

The growth of the global liver cirrhosis treatment market is driven by various factors such as an increasing global geriatric population, rising prevalence of liver cirrhosis, rapidly changing lifestyle, growing awareness programs regarding liver diseases, rising R&D investment for the development of innovative drugs for liver diseases, and increasing demand for better treatment methods for curing liver cirrhosis. However, stringent government regulations, high investment required for drug research & development, and side-effects of medications prescribed for liver cirrhosis are the factors that are expected to limit the growth of the global liver cirrhosis treatment market.

The global liver cirrhosis treatment market is currently dominated by several market players. The key players are involved in product launches and strategic collaborations to strengthen their market positions.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the increasing prevalence of liver cirrhosis and high geriatric population. The liver cirrhosis treatment market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European liver cirrhosis treatment market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The liver cirrhosis treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing patient pool of liver cirrhosis and raising awareness about the disease, the market in Asia-Pacific is expected to be the fastest-growing. The liver cirrhosis treatment market in the Middle East & Africa has been divided into the Middle East and Africa.

Segmentation

The global liver cirrhosis treatment market has been segmented based on treatment, and end user.

The global liver cirrhosis treatment market has been segmented, on the basis of treatment, into antibiotics, immunosuppressants, and others. The antibiotics segment is expected to hold the majority share of the market as antibiotics are the most preferred type of prescribed drugs for liver cirrhosis patients due to high risk of infections. The immunosuppressants segment is expected to grow at the fastest CAGR, due to an increasing number of liver transplants. Till October 2017, 147,842 liver transplants have been performed in the Americas. Immunosuppressants are a type of drugs that are prescribed to patients who have undergone liver transplant so that the risk of organ rejection is decreased. Other treatment options include drugs to reduce ammonia levels, antihypertensive drugs, and medications to reduce blood pressure, among others.

The market on the basis of end user has been segmented into hospitals and clinics, research and academic institutes, and others. The hospitals and clinics segment is expected to hold the largest share of the market as they are primary centers of treatment for the patient. Research and academic institutes carry out research activities for the development of new treatment options for liver cirrhosis. Other end users include home care settings and specific centers for the treatment of elderly people.

Key Players

Some of the key players in the global liver cirrhosis treatment market are Pfizer, Inc. (US), Merck & Co., Inc. (Germany), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Takeda Pharmaceutical Company Limited (Japan), Gilead Sciences, Inc. (US), AstraZeneca (UK), Bayer AG (Germany), Sanofi (France), Shionogi Inc. (Japan), and Promethera (Belgium).

Cell Lysis and Disruption Market 2020 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2027

Registering a CAGR of 8.6%, the Global Cell Lysis & Disruption Market size is expected to reach USD 5.7 Billion in by 2025.

The expanding biotechnology and biopharmaceutical sector are driving the growth of this market. For instance, firms in the U.S. firms perform extensive R&D in pharmaceuticals which is approximately USD 75 billion.

The market is dominated by numerous established players. The key players are involved in product launches and strategic collaborations to strengthen their market positions. For instance, in June 2018, Thermo Fisher Scientific acquired Gatan, Inc. from Roper Technologies for approximately USD 925 million.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8358

Market Influencers

The rising focus on personalized medicine would directly drive the growth of the global cell lysis & disruption market. Strategic initiatives, mergers & acquisitions, partnerships, agreements, product launches, government approvals, and expansion of manufacturing facilities by major competitors are expected to positively affect market growth during the forecast period.

Regional Analysis

On a regional basis, the Americas is anticipated to dominate the global cell lysis & disruption market owing to the growing clinical R&D budgets by both governments as well as public and private organizations in the pharmaceutical and biotech sector and increasing demand for novel therapeutics in the region. Additionally, the rising prevalence of geriatric population along with various chronic diseases is contributing to the growth of this market. According to a report by the Population Reference Bureau, the number of older population (aged 65 and above) will rise to nearly 24% from 15% by 2060. Europe is expected to hold the second-largest position in the global cell lysis & disruption market owing to the presence of a strong academic & research base and availability of funding for research in the European countries. Moreover, rising healthcare expenditure is boosting the market in this region. Asia-Pacific is anticipated to be the fastest-growing region is due to the growing interest of major key players in emerging markets and rapidly developing healthcare infrastructure in this region. The Middle East & Africa has the least share of the global cell lysis & disruption market. Moreover, the major market share of the region is expected to be held by the Middle East region owing to the increasing government initiatives for the healthcare sector.

Segmentation

The global cell lysis & disruption market has been segmented into technique, product, cell type, and end user.

By technique, the market has been segregated into reagent based and physical disruption. The reagent based segment has been further sub-segmented into detergent and enzymatic. The physical disruption further divided into mechanical homogenization, ultrasonic homogenization, pressure homogenization, and temperature treatments

By product, the market has been bifurcated into consumables and instruments. The consumables segment is estimated to hold major market share in the market due to the rise in funding of cell based research. Consumables has been further divided into reagent and kits, beads and disposables. The instrument segment has been further categorized as sonicators, homogenizers, French press, microfluidizer, and others.

On the basis of cell type, the global cell lysis & disruption market has been classified as mammalian cells, microbial cells, and others.

The global cell lysis & disruption market, by end user, has been divided into research laboratories and institutes, pharmaceutical and biotechnology companies, and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/cell-lysis-disruption-market-8358

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Alpha-1 Antitrypsin Deficiency Treatment Market Is Seeing Explosive Growth by Future Industry Winners: Forecast, 2020-2027

Global Alpha-1 Antitrypsin Deficiency Treatment Market is expected to cross USD 2,914.7 Million by 2025 at a CAGR of 10.50%.

Growing product pipeline for alpha-1 antitrypsin drugs and rising prevalence of alpha-1 antitrypsin deficiency are set to drive the market growth for alpha-1 antitrypsin deficiency treatment. Approximately 100,000 people in the US are known to suffer from alpha-1 antitrypsin deficiency.

Rising awareness regarding the alpha-1 antitrypsin deficiency is expected to drive the growth of the global alpha-1 antitrypsin deficiency treatment market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8319

The market is dominated by numerous established players. The key players are involved in product launches, strategic collaborations, and awareness programs to strengthen their market positions. For instance, in November 2018, Grifols S. A. launched the AlfaCare therapy program for training and counseling of patients diagnosed with alpha-1 antitrypsin deficiency.

Market Influencer

The prevalence of alpha-1 antitrypsin deficiency (AATD) is increasing, which is directly responsible for the growth of the global alpha-1 antitrypsin deficiency treatment market. Strategic initiatives, mergers & acquisitions, partnerships, agreements, product launches, government approvals, and expansion of manufacturing facilities by major competitors are expected to further boost market growth during the forecast period.

Segmentation

By Drugs:

Alpha-1 Proteinase Inhibitor: The segment is expected to hold the largest market share as it is the only treatment for AATD, which protects the patient from more lung damage.
Bronchodilators: These are used for the treatment of respiratory disorders associated with AATD.
Steroids: These are used specifically for the treatment of chronic obstructive pulmonary disease, which affects the patient along with AATD.
Others: Other treatment options include antibiotics for infections and jaundice associated with AATD and oxygen therapy.

By Route of Administration:

Oral: The segment is expected to hold the largest market share.
Intravenous: The segment is expected to grow at the fastest CAGR.
Inhalation: This route of administration is used specifically for the administration of corticosteroids for treating breathing disorders.
Others: Subcutaneous and intramuscular routes of administration.

By Distribution Channel:

Hospital Pharmacy: The rise in the number of hospitals is likely to be responsible for the largest market size.
Retail Pharmacy: These fulfill the requirement of drugs that are needed for treatment at home.
Online Stores: The fastest-growing segment owing to increase in number of online pharmacies.

By Region

Americas: The region holds the largest share of the market. The market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.

Europe: The European alpha-1 antitrypsin deficiency treatment market has been classified as Western Europe and Eastern Europe. The Western European market has further been categorized as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

Asia-Pacific: The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Asia-Pacific alpha-1 antitrypsin deficiency treatment market is projected to be the fastest-growing during the forecast period.

Middle East & Africa: The market in the Middle East & Africa has been divided into the Middle East and Africa.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/alpha-1-antitrypsin-deficiency-treatment-market-8319
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com